Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
What 4 Analyst Ratings Have To Say About BioCryst Pharmaceuticals
06:03pm, Monday, 18'th Apr 2022 Benzinga
Within the last quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
1
3
0
Why BioCryst Pharmaceuticals Stock Sank Today
05:40pm, Monday, 18'th Apr 2022
Another analyst gets notably less enthusiastic about the company's prospects.
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022
02:04pm, Monday, 18'th Apr 2022 Benzinga
Upgrades
For PBF Energy Inc (NYSE:PBF), Scotiabank upgraded the previous rating of Sector Underperform to Sector Perform. For the fourth quarter, PBF Energy had an EPS of $1.28, compared to year-ago q
Why BioChryst Pharmaceuticals' Stock Jumped 14.7% This Week
10:07pm, Thursday, 14'th Apr 2022 The Motley Fool
Investors returned to the stock after last week's sell-off.
Why BioChryst Pharmaceuticals' Stock Jumped 14.7% This Week
06:07pm, Thursday, 14'th Apr 2022
Investors returned to the stock after last week's sell-off.
28 Biggest Movers From Yesterday
12:15pm, Thursday, 14'th Apr 2022 Benzinga
Gainers
HighPeak Energy, Inc. (NASDAQ: HPK) shares gained 31.76% to close at $28.83 on Wednesday, after CNBC’s Jim Cramer said the mid-cap company is an aggressive play on elevated oil prices.
AVZ
Strength Seen in BioCryst (BCRX): Can Its 15.2% Jump Turn into More Strength?
09:35am, Thursday, 14'th Apr 2022 Zacks Investment Research
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Strength Seen in BioCryst (BCRX): Can Its 15.2% Jump Turn into More Strength?
06:47am, Thursday, 14'th Apr 2022
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2022
02:07pm, Monday, 11'th Apr 2022 Benzinga
Upgrades
Tudor Pickering upgraded the previous rating for EQT Corp (NYSE:EQT) from Hold to Buy. EQT earned $0.41 in the fourth quarter, compared to $0.02 in the year-ago quarter. At the moment, the st
Why BioCryst Pharmaceuticals Stock Is Falling
01:14pm, Monday, 11'th Apr 2022 Benzinga
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Monday morning after BofA Securities downgraded the stock and Oppenheimer lowered its price target.
BofA Securities analyst Tazee
BioCryst (BCRX) Pauses Enrolment in Key Studies, Stock Down
12:33pm, Monday, 11'th Apr 2022 Zacks Investment Research
BCX9930 is a BioCryst Pharmaceuticals' (BCRX) oral Factor D inhibitor being evaluated in several studies for the treatment of complement-mediated diseases
BioCryst to Present at Upcoming Investor Conference
12:30pm, Monday, 11'th Apr 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 21st Annual Needham Virtual Healt
BioCryst (BCRX) Pauses Enrolment in Key Studies, Stock Down
09:47am, Monday, 11'th Apr 2022
BCX9930 is a BioCryst Pharmaceuticals' (BCRX) oral Factor D inhibitor being evaluated in several studies for the treatment of complement-mediated diseases
Why BioCryst Pharmaceuticals Stock Is Falling
09:30am, Monday, 11'th Apr 2022
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Monday morning after BofA Securities downgraded the stock and Oppenheimer lowered its price target. BofA Securities analyst Tazee
BioCryst to Present at Upcoming Investor Conference
08:30am, Monday, 11'th Apr 2022
RESEARCH TRIANGLE PARK, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 21st Annual Needham Virtual Healthc
